Effect of an increased clopidogrel maintenance dose or lansoprazole co-administration on the antiplatelet response to clopidogrel in CYP2C19-genotyped healthy subjects

J Thromb Haemost. 2010 Mar;8(3):610-3. doi: 10.1111/j.1538-7836.2009.03729.x. Epub 2009 Dec 21.
No abstract available

Publication types

  • Clinical Trial
  • Letter
  • Research Support, Non-U.S. Gov't

MeSH terms

  • 2-Pyridinylmethylsulfinylbenzimidazoles / administration & dosage*
  • Adult
  • Aryl Hydrocarbon Hydroxylases / antagonists & inhibitors
  • Aryl Hydrocarbon Hydroxylases / genetics*
  • Aryl Hydrocarbon Hydroxylases / metabolism
  • Clopidogrel
  • Cytochrome P-450 CYP2C19
  • Dose-Response Relationship, Drug
  • Drug Interactions
  • Heterozygote
  • Homozygote
  • Humans
  • Lansoprazole
  • Male
  • Phenotype
  • Platelet Aggregation / drug effects*
  • Platelet Aggregation Inhibitors / administration & dosage*
  • Platelet Aggregation Inhibitors / metabolism
  • Polymorphism, Genetic*
  • Proton Pump Inhibitors / administration & dosage*
  • Ticlopidine / administration & dosage
  • Ticlopidine / analogs & derivatives*
  • Ticlopidine / metabolism
  • Young Adult

Substances

  • 2-Pyridinylmethylsulfinylbenzimidazoles
  • Platelet Aggregation Inhibitors
  • Proton Pump Inhibitors
  • Lansoprazole
  • Clopidogrel
  • Aryl Hydrocarbon Hydroxylases
  • CYP2C19 protein, human
  • Cytochrome P-450 CYP2C19
  • Ticlopidine